Amarin Corp Plc (AMRN)

[lettruthringout]

Stifel on Vascepa in Canada


Keywood’s newest report comes with updated analysis on Canadian prescription data for Vascepa in January 2022, which indicated an annual net sales run rate of $26 million, producing ten per cent sequential growth and a 330 per cent year-over-year increase.

“Public reimbursement negotiations for Vascepa are still active, according to the pCPA website, where updates could be imminent,” Keywood said. “Achievement of public reimbursement could inflect the demand curve and represents approximately 60 per cent of the peak sales opportunity, where private reimbursement has already been achieved.”

On top of the sales component, Keywood also noted that the company began its partnership with Pfizer in late September, and appears to be contributing to increased demand at higher prescription volumes. All told, Keywood estimates there are just over 9,000 prescriptions for Vascepa patients in Canada, with a long way to go before fulfilling the potential for more than 100,000 prescriptions.

https://www.cantechletter.com/2022/02/patience-should-mean-a-big-reward-on-hls-therapeutics-says-stifel/